Novel polypeptides and nucleic acids encoding same
OwnerKumud Majumderinventor
Life of this patent
Estimating the term…
Abstract
The present invention provides novel isolated NOVX polynucleotides and polypeptides encoded by the NOVX polynucleotides. Also provided are the antibodies that immunospecifically bind to a NOVX polypeptide or any derivative, variant, mutant or fragment of the NOVX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the NOVX polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.
Claims43
An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- a) a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO:
- 16 or 20;
- b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO:
- 16 or 20, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed;
- c) the amino acid sequence selected from the group consisting of SEQ ID NO:
- 16 or 20;
- d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO:
- 16 or 20 wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed;
- and
- e) a fragment of any of a) through d).
An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:
- a) a mature form of the amino acid sequence given SEQ ID NO:
- 16 or 20;
- b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO:
- 16 or 20 wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed;
- c) the amino acid sequence selected from the group consisting of SEQ ID NO:
- 16 or 20;
- d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO:
- 16 or 20, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed;
- e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:
- 16 or 20 or any variant of said polypeptide wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed;
- and
- f) the complement of any of said nucleic acid molecules.
A method for determining the presence of or predisposition to a disease associated with altered levels of the polypeptide of claim I in a first mammalian subject, the method comprising:
- a) measuring the level of expression of the polypeptide in a sample from the first mammalian subject;
- and
- b) comparing the amount of said polypeptide in the sample of step (a) to the amount of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, said disease,
- wherein an alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to said disease.
A method of treating a pathological state in a mammal, the method comprising administering to the mammal a polypeptide in an amount that is sufficient to alleviate the pathological state, wherein the polypeptide is a polypeptide having an amino acid sequence at least 95% identical to a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:
- 16 or 20 or a biologically active fragment thereof.
Dependencies are inferred from the claim text.